William Blair reaffirmed their outperform rating on shares of Retrophin (NASDAQ:RTRX) in a report published on Wednesday morning, Zacks.com reports.

Other equities research analysts have also recently issued research reports about the company. ValuEngine cut Retrophin from a strong-buy rating to a buy rating in a report on Thursday, January 17th. TheStreet cut Retrophin from a c- rating to a d+ rating in a report on Friday, February 22nd. BidaskClub cut Retrophin from a buy rating to a hold rating in a report on Friday, January 11th. Zacks Investment Research upgraded Retrophin from a strong sell rating to a hold rating in a report on Wednesday, February 27th. Finally, Svb Leerink restated an outperform rating on shares of Retrophin in a report on Tuesday, February 26th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $50.50.

RTRX opened at $20.05 on Wednesday. The company has a market capitalization of $830.81 million, a P/E ratio of -7.89 and a beta of 1.02. The company has a debt-to-equity ratio of 0.61, a quick ratio of 4.68 and a current ratio of 4.74. Retrophin has a 1-year low of $19.57 and a 1-year high of $33.00.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.42. The business had revenue of $43.77 million for the quarter, compared to analysts’ expectations of $43.54 million. Retrophin had a negative return on equity of 33.53% and a negative net margin of 62.51%. The company’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.07 EPS. As a group, equities research analysts forecast that Retrophin will post -2.47 earnings per share for the current fiscal year.

In related news, SVP William E. Rote sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $21.52, for a total value of $26,900.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Laura Clague sold 2,033 shares of the company’s stock in a transaction that occurred on Tuesday, February 12th. The shares were sold at an average price of $21.44, for a total value of $43,587.52. Following the completion of the sale, the chief financial officer now directly owns 11,016 shares in the company, valued at approximately $236,183.04. The disclosure for this sale can be found here. In the last ninety days, insiders sold 12,917 shares of company stock worth $277,140. 3.67% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of RTRX. Metropolitan Life Insurance Co. NY lifted its stake in Retrophin by 318.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,785 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 10,491 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Retrophin in the 3rd quarter valued at approximately $333,000. Legal & General Group Plc lifted its stake in Retrophin by 17.2% in the 4th quarter. Legal & General Group Plc now owns 15,866 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 2,325 shares in the last quarter. Ontario Teachers Pension Plan Board purchased a new stake in Retrophin in the 4th quarter valued at approximately $420,000. Finally, Assenagon Asset Management S.A. purchased a new stake in Retrophin in the 4th quarter valued at approximately $494,000.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Story: What causes a recession?

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.